A Phase I Study Of Docetaxel, Oxaliplatin, & Capecitabine (DOC) As First-Line Therapy of Patients With Locally Advanced or Metastatic Adenocarcinoma of Stomach and GE Junction

By Malik Imtiaz   Bernal Pedro   Byrd Janet  

Cancer Investigation, Vol. 28, Iss. 8, 2010-09 ,pp. : 833-838

Informa Healthcare

Access to resources Recommend Favorite

Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer

By Andersen Maria   Schønnemann Katrine R.   Yilmaz Mette   Jensen Helle A.   Vestermark Lene W.   Pfeiffer Per  

Acta Oncologica, Vol. 49, Iss. 8, 2010-11 ,pp. : 1246-1252

Informa Healthcare

Access to resources Recommend Favorite

Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer

By Dupont Jeanette   Jensen Helle A.   Jensen Benny V.   Pfeiffer Per  

Acta Oncologica, Vol. 46, Iss. 3, 2007-01 ,pp. : 330-335

Informa Healthcare

Access to resources Recommend Favorite

Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer

By  

Cancer Medicine, Vol. 2045-7634, Iss. 10, 2015-10 ,pp. : 1505-1513

John Wiley & Sons Inc

Access to resources Recommend Favorite

Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer

By Quek Richard   Lim Wan Teck   Foo Kian Fong   Koo Wen Hsin   A-Manaf Afidah   Toh Han Chong  

Acta Oncologica, Vol. 46, Iss. 7, 2007-01 ,pp. : 1032-1034

Informa Healthcare

Access to resources Recommend Favorite